PulseExploreJournal ClubTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 1, 2019BMJ Case ReportsOpen Access

Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach

View Full Paper
Ask AI
Bookmark
Share

Population

44-year-old woman with no relevant psychiatric history, admitted to a nephrology unit due to acute renal…

Design

Case_report

Follow-up

outpatient follow-up

Key result

A multimodal treatment approach involving electroconvulsive therapy and bromocriptine led to near full remission of symptoms in a 44-year-old woman with atypical neuroleptic malignant syndrome.

Authors

AVAna VelosaANAntónio Cruz NevesJBJ. Bernardo Barahona‐Corrêa

Discussion

Loading...

Member takes

Overview

May support multimodal ECT-bromocriptine in atypical NMS; leaves open need for controlled validation before broader adoption.

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
44-year-old woman with no relevant psychiatric history, admitted to a nephrology unit due to acute renal failure, who developed neuroleptic malignant syndrome after administration of antipsychotics
I
Intervention
Electroconvulsive therapy (ECT) followed by administration of a dopamine receptor agonist
O
Outcome
Remission of symptoms

Neuroleptic malignant syndrome can present atypically and be easily missed; a multimodal treatment approach including ECT should be considered, and post-NMS follow-up is crucial to investigate underlying neurological disorders like Parkinson's disease.

Limitations

  • Single case report limits generalizability
  • Lack of controlled evidence for ECT use in NMS

Cite This Study

Velosa et al. (2019) conducted a case report in Neuroleptic malignant syndrome (n=1). Electroconvulsive therapy (ECT) and bromocriptine was evaluated on Symptom remission measured by BPRS, BFCRS, and MoCA scores. A multimodal treatment approach involving electroconvulsive therapy and bromocriptine led to near full remission of symptoms in a 44-year-old woman with atypical neuroleptic malignant syndrome.

synapsesocial.com/papers/6a0ba8b04f6759c6fca253cehttps://doi.org/10.1136/bcr-2018-225840
View Full Paper
Ask AI
Bookmark
Share